EveliQure Biotechnologies GmbH

About:

EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine.

Website: https://www.eveliqure.com/

Top Investors: Kinled Holding, Arax Capital Partners

Description:

EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against Shigella as well as against ETEC bacteria. Both bacterial strains cause various types of diarrheal diseases, and all attempts at development of vaccines have so far only aimed to protect against one of the two bacterial strains. The team led by Managing Director Gábor Somogyi has succeeded for the first time in producing a combined swallow vaccine that simultaneously protects against both bacterial strains.